Cite

    Grace L. Johnson et al.. “CD34+ cell therapy significantly reduces adverse cardiac events, health care expenditures, and mortality in patients with refractory angina.” Stem cells translational medicine, vol. 9, 2020, pp. 1147–1152. http://access.bl.uk/ark:/81055/vdc_100110793246.0x000009